RAV

(redirected from RAVS)
Also found in: Dictionary, Acronyms.

RAV

Abbreviation for Rous-associated virus.

RAV

Abbreviation for Rous-associated virus.
Mentioned in ?
References in periodicals archive ?
Prevalence of Multiple RAVs. We also found that 87.5% (77/88) of the isolates showed two or more RAVs.
Little data have been published on the natural occurrence of viral variants in HCV genotype 6a; in our study, we investigate the RAVs in DAAs treatment-naive HCV-6ainfected patients.
RAVs to NS5A inhibitors are frequently detected as natural variants in HCV genotype 1 infected DAAs-naive patients.
In addition, we detected that 87.5% isolates harbor one or more RAVs. Chen et al.
Whether the multiple RAVs will interfere with the efficacy of IFN-free regimens deserves further studies.
Available data to date on RAVs is mainly from the study on HCV genotypes 1-5 and the effect of RAVs in genotype 6a is still not certain.
All of the RAVs detected by ultra-deep sequencing could be detected by population sequencing.
About 92.5% (148/160) of the patients were successfully amplified with the NS5A fragments, 14.9% (22/148) of whom presented at least one NS5A protein inhibitors RAVs. About 6.1% (9/148) of the patients presented Q30R variant, 8.8% (13/148) of the patients presented Q54H variant, 10.1% (14/148) of the patients presented Y93H variant.
Interestingly, the daclatasvir, LDV, and MK-8742 RAVs L31M have not been detected by population sequencing in any one of the 148 patients but have been detected by ultra-deep sequencing in 3 patients, with average mutation frequencies of 4.7%.
When considering RAVs of nucleoside inhibitors, 94.2% (129/137) of the patients were detected harboring the C316N variant.
It is worth-mentioning that some RAVs of nonnucleoside inhibitors were also detected in our study, such as V494A/T/L, V499A (thumb I); M423I/T, M424V, M426T (thumb II); H95Q, M414I/L, S556G/N (palm I); S365A/L/S/T (palm II), etc., Regarding the cross-resistance between these four categories, we have worked out the possible overlap of RAVs of different sorts of nonnucleoside inhibitors.
In our study, as many as 71% of genotype 1b treatment-naive patients presented at least one NS3/4A PIs RAV. The most prevalent variant was S122G (56.6%), which has been confirmed as one of the major RAVs of simeprevir (one of the first-generation second-wave PIs).[sup][11] In CONCERTO trial conducted in Japan, the baseline prevalence of S122G variant was relatively lower (34.9%) than that of our findings, while the baseline prevalence of V170I variant was relatively higher (39.6% vs.